Inhibikase Therapeutics Inc (IKT)

$1.90 -0.08 (-4.04%)
Market Cap 141.25M
Revenue (ttm) 0.00
Net Income (ttm) -27.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 162,800
Avg Vol 158,696
Day's Range N/A - N/A
Shares Out 74.34M
Stochastic %K 53%
Beta 1.02
Analysts Strong Sell
Price Target $8.00

Latest News on IKT

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Apr 14, 2025, 8:00 AM EDT - 5 days ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Mar 27, 2025, 4:01 PM EDT - 23 days ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Announces Expansion of Senior Leadership Team

Feb 24, 2025, 8:00 AM EST - 7 weeks ago

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Feb 18, 2025, 8:00 AM EST - 2 months ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Jan 29, 2025, 6:30 PM EST - 2 months ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Nov 19, 2024, 1:32 PM EST - 5 months ago

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Nov 14, 2024, 8:37 AM EST - 5 months ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 21, 2024, 9:05 AM EDT - 6 months ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Oct 9, 2024, 9:18 AM EDT - 6 months ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:13 PM EDT - 8 months ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 14, 2024, 4:25 PM EDT - 8 months ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 7, 2024, 8:00 AM EDT - 9 months ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 17, 2024, 8:05 AM EDT - 10 months ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Jun 5, 2024, 8:05 AM EDT - 11 months ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 20, 2024, 8:01 AM EDT - 11 months ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

May 17, 2024, 9:57 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:00 PM EDT - 1 year ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 15, 2024, 8:45 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

May 9, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Apr 3, 2024, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 5:13 PM EDT - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 27, 2024, 4:15 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 7, 2024, 8:30 AM EST - 1 year ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 28, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Feb 7, 2024, 7:55 AM EST - 1 year ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 29, 2024, 9:05 AM EST - 1 year ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Jan 16, 2024, 4:05 PM EST - 1 year ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Dec 4, 2023, 8:35 AM EST - 1 year ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Nov 15, 2023, 5:38 PM EST - 1 year ago

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 14, 2023, 4:30 PM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Nov 7, 2023, 9:28 AM EST - 1 year ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 24, 2023, 8:30 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 22, 2023, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 21, 2023, 8:30 AM EDT - 1 year ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 17, 2023, 8:30 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Aug 7, 2023, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 17, 2023, 4:05 PM EDT - 1 year ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 29, 2023, 9:29 AM EDT - 1 year ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 22, 2023, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

Jun 21, 2023, 8:05 AM EDT - 1 year ago

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

May 30, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript

May 16, 2023, 9:38 AM EDT - 2 years ago

Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

May 16, 2023, 7:45 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

May 8, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

May 4, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

Apr 26, 2023, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

Apr 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase